Therapeutic approaches for tumor necrosis factor inhibition

Brazilian Journal of Pharmaceutical Sciences

Volumn 47, Issue 3, 2011, Pages 427-446

  Barbosa, Maria Letícia de Castro ^a   Fumian, Milla Machado ^a   de Miranda, Ana Luísa Palhares ^a   Barreiro, Eliezer J ^a   Lima, Lídia Moreira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adenosine receptor; CAMP; NF B; P38 MAPK; Phosphodiesterase; TACE; Tumor necrosis factor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; ADALIMUMAB; ARPASTAT; BMS 561392; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DEXAMETHASONE; DORAMAPIMOD; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; LENALIDOMIDE; LYMPHOTOXIN; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PKF 241 466; PKF 242 484; RO 32 7315; RWJ 68 354; TALMAPIMOD; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; BRONCHITIS; CONTROLLED STUDY; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ERYTHEMA NODOSUM LEPROSUM; HUMAN; IMMUNOMODULATION; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LEPROMATOUS LEPROSY; MULTIPLE MYELOMA; NONHUMAN; PHARYNGITIS; PROTEIN FUNCTION; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SINUSITIS; ULCERATIVE COLITIS; URINARY TRACT INFECTION;

EID: 80055033316     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: 10.1590/S1984-82502011000300002     Document Type: Review

References (93)

1. ABREU, T. P. Estudo de derivados ftalimídicos análogos à talidomida: inibição do fator transcricional NF-κB e investigação da ação anti-angiogênica. Rio de Janeiro, 2007. 121 p. [Master's Degree Thesis in Genetics. Institute of Biology. Federal University of Rio de Janeiro].
2. ADAMS, J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today, v.8, n.7, p.307-315, 2003.
3. ALEXANDRE-MOREIRA, M.S.; TAKIYA, C.M.; ARRUDA, L.B., PASCARELLI, B.; GOMES, R.N.; FARIA NETO, H.C.; LIMA, L. M.; BARREIRO, E. J. LASSBio-468: a new achiral thalidomide analogue with modulates TNF-α and NO production and inhibits endotoxic shock and arthritis in na animal model. Int. Immunopharmacol., v.5, n.3, p.485-494, 2005.
4. ARANAPAKAM, V.; DAVIS, J.M.; GROSU, G.T.; BAKER, J.; ELLINGBOE, J.; ZASK, A.; LEVIN, J.I.; SANDANAYAKA, V.P.; DU, M.; SKOTNICKI, J.S.; DIJOSEPH, J.F.; SUNG, A.; SHARR, M.A.; KILLAR, L.M.; WALTER, T.; JIN, G.; COWLING, R.; TILLETT, J.; ZHAO, W.; MCDEVITT, J.; XU, Z.B. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem., v.46, n.12, p.2376-2396, 2003.
5. BANNER, D. W.; D'ARCY, A.; JANES, W.; GENTZ, R.; SCHOENFELD, H-J.; BROGER, C.; LOETSCHER, H.; LESSLAUER, W. Crystal structure of the soluble human 55kDa TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell, v.73, n.3, p.431-445, 1993.
6. BECK, G.; BOTTOMLEY, G.; BRADSHAW, D.; BREWSTER, M.; BROADHURST, M.; DEVOS, R.; HILL, C.; JOHNSON, W.; KIM, H.J.; KIRTLAND, S.; KNEER, J.; LAD, N.; MACKENZIE, R.; MARTIN, J.; NIXON, J.; PRICE, G.; RODWELL, A.; ROSE, F.; TANG, J.P.; WALTER, D.S.; WILSON, K.; WORTH, E. (E)-2(R)-[1(S)-(hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-α convertase. J. Pharmacol. Exp. Ther., v.302, n.1, p.390-396, 2002.
7. BLACK, R. A.; BIRD, T. A., MOHLER, K. M. Agents that block TNF-α synthesis or activity. Annu. Rep. Med. Chem., v.32, p.241-249, 1997.
8. BOEHM, J. C.; SMIETANA, J. M.; SORENSON, M. E.; GARIGIPATI, R. S.; GALLAGHER, T. F.; SHELDRAKE, P. L.; BRADBEER, J.; BADGER, A. M.; LAYDON, J. T.; LEE, J. C.; HILLEGASS, L. M.; GRISWOLD, D. E.; BRETON, J. J.; CHABOT-FLETCHER, M. C.; ADAMS, J. L. 1-Substituted 4-Aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J. Med. Chem., v.39, n.20, p.3929-3937, 1996.
9. BOSWELL-SMITH, V.; SPINA, D.; PAGE, C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol., v.147, n. S1, p. S252-S257, 2006.
10. BRAKEBUSCH, C.; VARFOLOMEEV, E.E.; BATKIN, M.; WALLACH, D. Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J. Biol. Chem., v.269, n.51, p.32488-32496, 1994.
11. BURKE, J.R.; PATTOLI, M.A.; GREGOR, K.R.; BRASSIL, P.J.; MACMASTER, J.F.; MCINTYRE, K.W.; YANG, X.; IOTZOVA, V.S.; CLARKE, W.; STRNAD, J.; QIU, Y.; ZUSI, C. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NFκB-dependent transcription in mice. J. Biol. Chem., v.278, n.3, p.1450-1456, 2003.
12. CAPORALI; R.; PALLAVICINI, F.B.; FILIPPINI, M.; GORLA, R.; MARCHESONI, A.; FAVALLI, E.G.; SARZI-PUTTINI, P.; ATZENI, F.; MONTECUCCO, C. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmun. Rev., v.8, n.3, p.274-280, 2009.
13. CAWTHORN, W.P.; SETHI, J.K. TNF-α and adipocyte biology. FEBS Letters, v.582, n.1, p.117-131, 2008.
14. CHERNEY, R.J.; KING, B.W.; GILMORE, J.L.; LIU, R.Q.; COVINGTON, M.B.; DUAN, J.J.W.; DECICCO, C.P. Conversion of potent MMP inhibitors into selective TACE inhibitors. Bioorg. Med. Chem. Lett., v.16, n.4, p.1028-1031, 2006.
15. CHUNG, K.F. Phosphodiesterase inhibitors in airways disease. Eur. J. Pharmacol., v.533, n.1-3, p.110-117, 2006.
16. CORRAL, L.G.; KAPLAN, G. Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis., v.58, suppl.1, p. l107-l113, 1999.
17. DASGUPTA, S.; MURUMKAR, P.R.; GIRIDHAR, R.; YADAV, M.R. Current perspective of TACE inhibitors: A review. Bioorg. Med. Chem., v.17, n.2, p.444-459, 2009.
18. DENG, L.; DING, W.; GRANSTEIN, R.D. Thalidomide inhibits tumor necrosis factor-α production and antigen presentation by Langerhans cells. J. Invest. Dermatol., v.121, n.5, p.1060-1065, 2003.
19. DE-BLANCO, E.J.C.; PANDIT, B.; HU, Z.; SHI, J.; LEWIS, A.; LI, P.K. Inhibitors of NF-kB derived from thalidomide. Bioorg. Med. Chem. Lett., v.17, n.21, p.6031-6035, 2007.
20. DUAN, J.J.W.; CHEN, L.; WASSERMAN, Z.R.; LU, Z.; LIU, R.Q.; COVINGTON, M.B.; QIAN, M.; HARDMAN, K.D.; MAGOLDA, R.L.; NEWTON, R.C.; CHRIST, D.D.; WEXLER, R.R.; DECICCO, C.P. Discovery of g-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor-α converting enzyme: design, synthesis, and structure-activity relationships. J. Med. Chem., v.45, n.23, p.4954-4957, 2002.
21. EDWARDS, M.R.; BARTLETT, N.W.; CLARKE, D.; BIRRELL, M.; BELVISI, M.; JOHNSTON, S.L. Targeting the NF-kB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol. Ther., v.121, n.1, p.1-13, 2009.
22. FELDMANN, M.; BRENNAN, F.M.; FOXWELL, B.M.J.; TAYLOR, P.C.; WILLIAMS, R.O.; MAINI, R.N. Anti-TNF therapy: where have we got to in 2005? J. Autoimmun., v.25, suppl.1, p.26-28, 2005.
23. FREDHOLM, B.B.; IJZERMAN, A.P.; JACOBSON, K.A.; KLOTZ, K.N.; LINDEN, J. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev., v.53, n.4, p.527-552, 2001.
24. GALLANT, M.; CHAURET, N.; CLAVEAU, D.; DAY, S.; DESCHÊNES, D.; DUBÉ, D.; HUANG, Z.; LACOMBE, P.; LALIBERTÉ, F.; LÉVESQUE, J-F; LIU, S.; MACDONALD, D.; MANCINI, J.; MASSON, P.; MASTRACCHIO, A.; NICHOLSON, D.; NICOLL-GRIFFITH, D.A.; PERRIER, H.; SALEM, M.; STYHLER, A.; YOUNG, R.N.; GIRARD, Y. Design, synthesis and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. Bioorg. Med. Chem. Lett., v.18, n.4, p.1407-1412, 2008.
25. GEARING, A. J. H.; BECKETT, P.; CRISTODOULOU, M.; DRUMMOND, A. H.; GALLOWAY, W. A.;GILBERT, R.; GORDON, J. L.; LEBER, T. M.; MAGAN, M.; MILLER, K.; NAYEE, P.; OWEN, K.; PATEL, S.; THOMAS, G.; WELLS, G.; WOOD, L. M.; WOOLLEY, K. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature, v.370, n.6490, p.555-557, 1994.
26. GRAY, P. W.; AGGARWAL, B. B.; BENTON, C. V.; BRINGMAN, T. S.; HENZEL, W. J.; JARRETT, J. A.; LEUNG, D. W.; MOFFAT, B.; NG, P.; SVEDERSKY, L. P.; PALLADINO, M. A.; NEDWIN, G. E. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature, v.312, n.5996, p.721-724, 1984.
27. HANADA, T.; YOSHIMURA, A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev., v.13, n.4, p.413-421, 2002.
28. HASHIMOTO, Y. Structural development of biological response modifiers based on thalidomide. Bioorg. Med. Chem., v.10, n.3, p.461-479, 2002.
29. HASKÓ, G.; CRONSTEIN, B.C. Adenosine: an endogenous regulator of innate immunity. Trends Immunol., v.25, n.1, p.33-39, 2004.
30. HENRY, J. R.; RUPERT, K. C.; DODD, J. H.; TURCHI, I. J.; WADSWORTH, S. A.; CAVENDER, D. E.; FAHMY, B.; OLINI, G. C.; DAVIS, J. E.; PELLEGRINO-GENSEY, J.; SCHAFER, P. H.; SIEKIERKA, J. J. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor. J. Med. Chem., v.41, n.22, p.4196-4198, 1998.
31. HOCHBERG, M.C.; LEBWOHL, M.G.; PLEVY, S.E.; HOBBS, K.F.; YOCUM, D.E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Sem. Arthritis Rheum., v.34, n.6, p.819-836, 2005.
32. HORSSEN, R.V.; HAGEN, T.L.M.; EGGERMONT, A.M.M. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, v.11, p.397-408, 2006.
33. HOUSLAY, M.D.; SCHAFER, P.; ZHANG, K.Y.J. Keynote review: Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today, v.10, n.22, p.1503-1519, 2005.
34. JACOBSON, K.A.; GAO, Z.G. Adenosine receptor as therapeutic targets. Nat. Rev. Drug Discov., v.5, n.3, p.247-264, 2006.
35. KANG, Y.J.; CHEN, J.; OTSUKA, M.; MOLS, J.; REN, S.; WANG, Y.; HAN, J. Macrophage deletion of p38α partially impairs lipopolysaccharide-induced cellular activation. J. Immunol., v.180, n.7, p.5075-5082, 2008.
36. KARIN, M. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappa B activation and prevention of apoptosis. J. Exp. Med., v.189, n.11, p.1839-1845, 1999.
37. KENNY, P.A. TACE: a new target in epidermal growth factor receptor depedent tumors. Differentiation, v.75, n.9, p.800-808, 2007.
38. KEIFER, J.; GUTTRIDGE, D.; ASHBURNER, B.; BALDWIN, A. Inhibition of NFκB activity by Thalidomide through suppression of IκB Kinase activity. J. Biol. Chem., v.276, n.25, p.22382-22387, 2001.
39. KIM, Y.S.; KIM, J.S.; JUNG, H.C.; SONG, I.S. The effects of thalidomide on the stimulation of NF-κappaB activity and TNF-alpha production by lipopolysaccharide in human colonic epithelial cell line. Mol. Cell, v.17, n.2, p.210-216, 2004.
40. KIM, D.K.; LIM, J.H.; LEE, J.A.; DEWANG, P.M. Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38α mitogen-activated protein kinase. Bioorg. Med. Chem. Lett., v.18, n.14, p.4006-4010, 2008.
41. KISHORE, N.; SOMMERS, C.; MATHIALAGAN, S.; GUZOVA, J.; YAO, M.; HAUSER, S.; HUYNH, K.; BONAR, S.; MIELKE, C.; ALBEE, L.; WEIER, R.; GRANETO, M.; HANAU, C.; PERRY, T.; TRIPP, C.S. A selective IKK-2 inhibitor blocks NFκB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J. Biol. Chem., v.278, n.35, p.32861-32871, 2003.
42. KNOWLTON, A. A. NFκB, heat shock proteins, HSF-1, and inflammation. Cardiovasc. Res., v.69, n.1, p.7-8, 2006.
43. KUMAR, S.; BOEHM, J.; LEE, J.C. p38 MAP kinases: key signaling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov., v.2, n.9, p.717-726, 2003.
44. LEVIN, J.I.; CHEN, J.M.; LAAKSO, L.M.; DU, M.; SCHMID, J.; XU, W.; CUMMONS, T.; XU, J.; JIN, G.; BARONE, D.; SKOTNICKI, J.S. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg. Med. Chem. Lett., v.16, n.6, p.1605-1609, 2006.
45. LIMA, L.M.; CASTRO, P.; MACHADO, A.L.; FRAGA, C.M.A.; LUGNIER, C.; MORAES, V.L.G.; BARREIRO, E.J. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg. Med. Chem., v.10, n.9, p.3067-3073, 2002.
46. LIMA, L.M.; FRAGA, C.A.M.; KOATZ, V.L.G.; BARREIRO, E.J. Thalidomide and analogs as anti-inflammatory and immunomodulator drug candidates. Anti-inflamm. Anti-allergy Agents Med. Chem., v.5, n.1, p.79-95, 2006.
47. LIN, J.; ZIRING, D.; DESAI, S.; KIM, S.; WONG, M.; KORIN, Y.; BRAUN, J.; REED, E. GJERTSON, D.; SINGH, R.R. TNFα blockade in human diseases: An overview of efficacy and safety. Clin. Immunol., v.126, n.1, p.13-30, 2008.
48. LIPWORTH, B. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, v.365, n.9454, p.167-175, 2005.
49. LIVERTON, N.J.; BUTCHER, J.W.; CLAIBORNE, C.F.; CLAREMON, D.A.; LIBBY, B.E.; NGUYEN, K.T.; PITZENBERGER, S.M.; SELNICK, H.G.; SMITH, G.R.; TEBBEN, A.; VACCA, J.P.; VARGA, S.L.; AGARWAL, L.; DANCHECK, K.; FORSYTH, A.J.; FLETCHER, D.S.; FRANTZ, B.; HANLON, W.A.; HARPER, C.F.; HOFSESS, S.J.; KOSTURA, M.; LIN, J.; LUELL, S.; O'NEILL, E.A.; OREVILLO, C.J.; PANG, M.; PARSONS, J.; ROLANDO, A.; SAHLY, Y.; VISCO, D.M.; O'KEEFE, S.J. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem., v.42, n.12, p.2180-2190, 1999.
50. MAN, H.W.; CORRAL, L.G.; STIRLING, D.I.; MULLER, G.W. a-Fluoro-substituted thalidomide analogues. Bioorg. Med. Chem. Lett., v.13, n.20, p.3415-3417, 2003.
51. MARRIOTT, J. B.; WESTBY, M.; DALGLEISH, A. G. Therapeutic potential of TNF-α inhibitors old and new. Drug Discov. Today, v.2, n.7, p.273-282, 1997.
52. MATTHEWS, S.J.; McCOY, C. Thalidomide: A review of approved and investigational uses. Clin. Ther., v.25, n.2, p.342-395, 2003.
53. MELCHERT, M.; LIST, A. The thalidomide saga. Int. J. Biochem. Cell Biol., v.39, n.7-8, p.1489-1499, 2007.
54. MERCURIO, F.; MANNING, A. M. Multiple signals converging on NF-κB. Curr. Opin. Cell Biol., v.11, n.2, p.226-232, 1999.
55. MOHAN, M.J.; SEATON, T.; MITCHELL, J.; HOWE, A.; BLACKBURN, K.; BURKHART, W.; MOYER, M.; PATEL, I.; WAITT, G.M.; BECHERER, D.; MOSS, M.L.; MILLA, M.E. The tumor necrosis factor alpha converting ezyme (TACE): A unique metalloproteinase with highly defined substrate selectivity. Biochemistry, v.41, n.30, p.9462-9469, 2002.
56. MONTALBAN, A.G.; BOMAN, E.; CHANG, C.D.; CEIDE, S.C.; DAHL, R.; DALESANDRO, D.; DELAET, N.G.J.; ERB, E.; ERNST, J.T.; GIBBS, A.; KAHL, J.; KESSLER, L.; LUNDSTRÖM, J.; MILLER, S.; NAKANISHI, H.; ROBERTS, E.; SAIAH, E.; SULLIVAN, R.; WANG, Z.; LARSON, C.J. The design and synthesis of novel a-ketoamide-based p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett., v.18, n.6, p.1772-1777, 2008.
57. MONTANA, J.G.; BUCKLEY, G.M.; COOPER, N.; DYKE, H.J.; GOWERS, L.; GREGORY, J.P.; HELLEWELL, P.G.; KENDALL, H.J.; LOWE, C.; MAXEY, R.; MIOTLA, J.; NAYLOR, R.J.; RUNCIE, K.A.; TULADHAR, B.; WARNECK, J.B.H. Aryl sulfonamides as selective PDE4 inhibitors. Bioorg. Med. Chem. Lett., v.8, n.19, p.2635-2640, 1998.
58. MOREIRA, A.L.; SAMPAIO, E.P.; ZMUIDZINAS, A.; FRINT, P.; SMITH, K.A.; KAPLAN, G. Talidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J. Exp. Med., v.177, n.6, p.1675-1680, 1993.
59. MOSS, M. L.; JIN, S. L. C.; MILLA, M. E.; BURKHART, W.; CARTER, H.L.; CHEN, W. J.; DIDSBURY, J. R.; HASSIER, D.; HOFFMAN, C. R.; KOST, T. A.; LAMBERT, M. H.; LEESNITZER, M. A.; McCAULEY, P.; McGEEHAN, G.; MITCHELL, J.; MOYERS, M.; PAHEL, G.; ROCQUE, W.; OVERTON, L. K.; SCHOENEN, F.; SEATON, T.; SU, J.L.; WARNER, J.; WILLARD, D.; BECHERE, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumor necrosis factor-alpha. Nature, v.385, n.6618, p.733-736, 1997.
60. MUKHOPADHYAY, S.; HOIDAL, J. R.; MUKHERJEE, T. K. Role of TNF-α in pulmonary pathophysiology. Respir. Res., v.7, n.125, p.1-9, 2006.
61. MULLER, G.; SHIRE, M.G.; WONG, L.; CORRAL, L.G.; PATTERSON, R.; CHEN, Y.; STIRLING, D. Thalidomide analogs and PDE4 inhibition. Bioorg. Med. Chem. Lett., v.8, n.19, p.2669-2674, 1998.
62. MULLER, G.; CHEN, R.; HUANG, S.; CORRAL, L.; WONG, L.; PATTERSON, R.; CHEN, Y.; KAPLAN, G.; STIRLING, D. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett., v.9, n.11, p.1625-1630, 1999.
63. MUTALIK, V.K.; VENKATESH, K.V. Effect of the MAPK cascade structure, nuclear translocation and regulation of transcription factors on gene expression. BioSystems, v.85, n.2, p.144-157, 2006.
64. NG, S.S.W.; BROWN, M.; FIGG, W.D. Thalidomide, an antiangiogenic agent with clinical activity in cancer. Biomed. Pharmacother., v.56, n.4, p.194-199, 2002.
65. PALLADINO, M. A.; BAHJAT, F. R.; THEODORAKIS, E. A.; MOLDAWER, L. L. Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov., v.2, n.9, p.736-746, 2003.
66. PAPPAS, D.A.; BATHON, J.M.; HANICQ, D.; YASOTHAN, U.; KIRKPATRICK, P. Golimumab. Nat. Rev. Drug Discov., v.8, n.9, p.695-696, 2009.
67. PAUL, A.T.; GOHIL, V.M.; BHUTANI, K.K. Modulating TNF-α signaling with natural products. Drug Discov. Today, v.11, n.15-16, p.725-732, 2006.
68. PENNICA, D.; NEDWIN, G. E.; HAYFLICK, J. S.; SEEBURG, P. H.; DERYNCK, R.; PALLADINO, M. A.; KOHR, W. J.; AGGARWAL, B. B.; GOEDDEL, D. V. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature, v.312, n.5596, p.724-729, 1984.
69. PETERSON, P.K.; HU, S.; SHENG, W.S.; KRAVITZ, F.H.; MOLITOR, T.W.; CHATTERJEE, D.; CHAO, CC. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide and lipoarabinomannan-stimulated human microglial cells. J. Infect. Dis., v.172, n.4, p.1137-1140, 1995.
70. PIERCE, J.W.; SCHOENLEBER, R.; JESMOK, G.; BEST, J.; MOORE, S.A.; COLLINS, T.; GERRITSEN, M.E. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem., v.272, n.34, p.21096-21103, 1997.
71. PODOLIN, P.L.; CALLAHAN, J.F.; BOLOGNESE, B.J.; LI, Y.H.; CARLSON, K.; DAVIS, T.G.; MELLOR, G.W.; EVANS, C.; ROSHAK, A.K. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TCPA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J. Pharmacol. Exp. Ther., v.312, n.1, p.373-381, 2005.
72. QIAN, M.; BAI, S.A.; BROGDON, B.; WU, J.T.; LIU, R.Q.; COVINGTON, M.B.; VADDI, K.; NEWTON, R.C.; FOSSLER, M.J.; GARNER, C.E.; DENG, Y.; MADUSKUIE, T.; TRZASKOS, J.; DUAN, J.J.W.; DECICCO, C.P.; CHRIST, D.D. Pharmacokinetics and pharmacodynamics of DPC 333 (2R)-2-(3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide), a potent and selective inhibitor of tumor necrosis factor α-converting enzyme in rodents, dogs, chimpanzees and humans. Drug Metab. Dispos., v.35, n.10, p.1916-1925, 2007.
73. ROUX, P.P.; BLENIS, J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev., v.68, n.2, p.320-344, 2004.
74. SACK, M.N. Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol. Ther., v.94, n.1-2, p.123-135, 2002.
75. SAMPAIO, E. P.; SARNO, E. N.; GALILLY, R.; COHN, Z.A.; KAPLAN, G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med., v.173, n.3, p.699-703, 1991.
76. SAMPAIO, E. P.; HERNANDEZ, M. O.; CARVALHO, D. S.; SARNO, E. N. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNF production in vitro. Biomed. Pharmacother., v.56, n.1, p.13-19, 2002.
77. SAMPAIO, E.P.; CARVALHO, D.S.; NERY, J.A.C.; LOPES, U.G.; SARNO, E.N. Thalidomide: An overview of its pharmacological mechanisms of action. Anti-Inflamm. Anti-Allergy Agents Med. Chem., v.5, n.1, p.71-77, 2006.
78. SHIMIZU, S.; YAMADA, Y.; OKUNO, M.; OHNISHI, H.; OSAWA, Y.; SEISHIMA, M.; MORIWAKI, H. Liver injury induced by lipopolysaccharide is mediated by TNFR-1 but not by TNFR-2 or Fas in mice. Hepatol. Res., v.31, n.3, p.136-142, 2005.
79. SIROHI, B.; POWLES, R. Multiple Myeloma. Lancet, v.363, n.9412, p.875-887, 2004.
80. SMITH, S.; SKERRETT, S.J.; CHI, E.Y.; JONAS, M.; MOHLER, K.; WILSON, C.B. The locus of Tumor Necrosis Factor alpha action in lung inflammation. Am. J. Respir. Cell Mol. Biol., v.19, n.6, p.881-891, 1998.
81. STEINWURZ, F. Experiência clínica com o uso de Infliximab em 44 portadores de doença de Crohn. Arq. Gastroenterol., v.40, n.3, p.198-200, 2003.
82. SURYAPRASAD, A.G.; PRINDIVILLE, T. The biology of TNF blockade. Autoimmun. Rev., v.2, n.6, p.346-357, 2003.
83. TARTAGLIA, L. A.; PENICCA, D.; GOEDDEL, D. V. Ligand passing: The 75-kDa Tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J. Biol. Chem., v.268, n.25, p.18542-18548, 1993.
84. TAYLOR, P.C. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr. Opin. Pharmacol. v.10, n.3, p.308-315, 2010.
85. TEO, S.K.; STIRLING, D.I.; ZELDIS, J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today, v.10, n.2, p.107-113, 2005.
86. TRACEY, D.; KLARESKONG, L.; SASSO, E.H.; SALFELD, J.G.; TAK, P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther., v.117, n.2, p.244-279, 2008.
87. TRIFILIEFF, A.; WALKER, C.; KELLER, T.; KOTTIRSCH, G.; NEUMANN, U. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. J. Pharmacol., v.135, n.7, p.1655-1664, 2002.
88. VOORHEES, P.M.; ORLOWSKI, R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol., v.46, p.189-313, 2006.
89. WEN, D.; NONG, Y.; MORGAN, J.G.; GANGURDE, P.; BIELECKI, A.; DASILVA, J. KEAVENEY, M.; CHENG, H.; FRASER, C.; SCHOPF, L.; HEPPERLE, M.; HARRIMAN, G.; JAFFEE, B.D.; OCAIN, T.D.; XU, Y. A selective small molecule IκB kinase β inhibitor blocks nuclear factor kB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J. Pharmacol. Exp. Ther., v.317, n.3, p.989-1001, 2006.
90. YAMAMOTO, S.; SUGAHARA, S.; IKEDA, K.; SHIMIZU, Y. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur. J. Pharmacol., v.559, n.2-3, p.219-226, 2007.
91. ZHANG, J.G.; HEPBURN, L.; CRUZ, G.; BORMAN, R.A.; CLARK, K.L. The role of adenosine A2A and A2B receptors in the regulation of TNF-α production by human monocytes. Biochem. Pharmacol., v.69, n.6, p.883-889, 2005.
92. ZHANG, J.; SHEN, B.; LIN, A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci., v.28, n.6, p.286-295, 2007.
93. ZUANY-AMORIN, C.; HASTEWELL, J.; WALKER, C. Toll-like receptors as potential targets for multiple diseases. Nat. Rev. Drug Discov., v.1, n.10, p.797-807, 2002.